A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis

References

• Smolen JS, Aletaha D. McInnes IB, Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
   Google Scholar
• Aletaha D. Smolen JS, Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360–1372.
   Google Scholar
• Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170:ITC1–ITC16.
   Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2015;2016(68):1–26.
   Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
   Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
   Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;2010(62):2569–2581.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;2010(69):1580–1588.
   Google Scholar
• Jung JY, Kim JW, Kim HA. Suh CH. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2019;19:979–986.
   Google Scholar
• Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol. 2017;10:923–933.
   Google Scholar
• Tavakolpour S, Alesaeidi S, Darvishi M, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019;38:2977–2994.
   Google Scholar
• McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865–867.
   Google Scholar
• Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388:239–247.
   Google Scholar
• European Medicines agency. Truxima® SmPC (summary of product characteristics). 11 Oct 2019. [Cited 2020 Jun 30]. Avaiable from: https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Mabthera® SmPC (summary of product characteristics). 10 Oct 2019. [Cited 2020 Jun 30]. Avalable from: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf.
   Google Scholar
• Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859–866.
   Google Scholar
• United States Food and Drug Administration. Truxima® USPI (United States Prescribing Information). 18 Dec 2019. [Cited 2020 Jun 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf
   Google Scholar
• European Medicines Agency. Rituximab. 30 June 2020. [Cited 2020 Jun 30]. Available from: https://www.ema.europa.eu/en/medicines/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar?search_api_views_fulltext=rituximab]
   Google Scholar
• United States Food and Drug Administration. FDA approved biosimilar product. 11 June 2020. [Cited 2020 Jun 30]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
   Google Scholar
• Generics and Biosimilar Initiative. Rituximab biosimilar submitted to EMA and Rituxan gains extra indication. 20 July 2018 Avalable from: [Cited 2020 Jun 30]. http://www.gabionline.net/Biosimilars/News/Rituximab-biosimilar-submitted-to-EMA-and-Rituxan-gains-extra-indication
   Google Scholar
• Clinicaltrials.gov. Clinical trials with Rituximab in rheumatoid arthritis. [Cited 2020 Jun 30]. Available from: https://clinicaltrials.gov/ct2/results?cond=Rheumatoid±Arthritis&term=rituximab&cntry=&state=&city=&dist
   Google Scholar
• Lee KH, Lee J, Bae JS, et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. MAbs. 2018;10:380–396.
   Google Scholar
• Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566–570.
   Google Scholar
• Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled phase 3 trial. MAbs. 2018;10:934–943.
   Google Scholar
• Shim SC, Bozic-Majstorovic L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford). 2019;58:2193–2202.
   Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31:369–377.
   Google Scholar
• Suh CH, Yoo DH, Berrocal Kasay A, et al. Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs. 2019;33:79–91.
   Google Scholar
• Jimenez Morales A, Maldonado-Montoro M, Martinez de la Plata JE, et al. FCGR2A/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis. J Clin Pharmacol. 2019;59:517–531.
   Google Scholar
• Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95.
   Google Scholar
• Daien CI, Fabre S, Rittore C, et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine. 2012;79:471–475.
   Google Scholar
• Ruyssen-Witrand A, Rouanet S, Combe B, Constantin A, et al. Association between −871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford). 2013;52:636–641.
   Google Scholar
• Yoo DH, Suh CH, Shim SC, et al. Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. BioDrugs. 2017;31:357–367.
   Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400.
   Google Scholar
• Mease PJ, Cohen S, Gaylis NB, Kelman A, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917–927.
   Google Scholar
• Tak PP, Rigby W, Rubbert-Roth A, Shaw T, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351–357.
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   Google Scholar
• Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol. 2018;14:727–740.
   Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, van den Hoogen FHJ, den Broeder AA:, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60–68.
   Google Scholar